Plaque assessment by coronary CT angiography may predict cardiac events in high risk and very high risk diabetic patients: A long-term follow-up study.


Journal

Nutrition, metabolism, and cardiovascular diseases : NMCD
ISSN: 1590-3729
Titre abrégé: Nutr Metab Cardiovasc Dis
Pays: Netherlands
ID NLM: 9111474

Informations de publication

Date de publication:
03 2022
Historique:
received: 14 06 2021
revised: 04 11 2021
accepted: 23 11 2021
pubmed: 4 2 2022
medline: 11 3 2022
entrez: 3 2 2022
Statut: ppublish

Résumé

The aim of the present study is to evaluate whether advanced coronary atherosclerosis analysis by CCTA may improve prognostic stratification among diabetic patients at high cardiovascular risk (CV risk). The study population consisted of 265 consecutive diabetic patients at high CV risk who underwent CCTA for suspected CAD between January 2011 and December 2016. For every patients both traditional and advanced, qualitative and quantitative coronary plaque analysis were performed. The occurrence of cardiac death, ACS, and non-urgent revascularization were recorded at follow-up. Among the 265 patients enrolled, 21 were lost to follow-up, whereas 244 (92%) had a complete follow-up (mean 45 ± 22 months) and were classified at high (n = 67) or very high cardiovascular risk (n = 177), according to ESC Guidelines. A total of 63 events were recorded (3 Cardiac Death, 3 NSTEMI, 8 unstable angina, 36 late non-urgent revascularization and 13 non-cardiac death) in 57 different patients. Elevated fibro-fatty plaque volume was the only predictor of events over age, gender and traditional risk factor when ACS and MACE were considered as end-points [HR (95% CI) 6.01 (1.65-21.87), p = 0.006 and 3.46 (2.00-5.97); p < 0.001]. The present study confirms the prognostic role of advance coronary atherosclerosis evaluation beyond risk factors and stenosis severity, even in diabetics. Despite the very high cardiovascular risk of study population, a not negligible portion (23%) of patients exhibited totally normal coronaries.

Sections du résumé

BACKGROUND AND AIMS
The aim of the present study is to evaluate whether advanced coronary atherosclerosis analysis by CCTA may improve prognostic stratification among diabetic patients at high cardiovascular risk (CV risk).
METHODS AND RESULTS
The study population consisted of 265 consecutive diabetic patients at high CV risk who underwent CCTA for suspected CAD between January 2011 and December 2016. For every patients both traditional and advanced, qualitative and quantitative coronary plaque analysis were performed. The occurrence of cardiac death, ACS, and non-urgent revascularization were recorded at follow-up. Among the 265 patients enrolled, 21 were lost to follow-up, whereas 244 (92%) had a complete follow-up (mean 45 ± 22 months) and were classified at high (n = 67) or very high cardiovascular risk (n = 177), according to ESC Guidelines. A total of 63 events were recorded (3 Cardiac Death, 3 NSTEMI, 8 unstable angina, 36 late non-urgent revascularization and 13 non-cardiac death) in 57 different patients. Elevated fibro-fatty plaque volume was the only predictor of events over age, gender and traditional risk factor when ACS and MACE were considered as end-points [HR (95% CI) 6.01 (1.65-21.87), p = 0.006 and 3.46 (2.00-5.97); p < 0.001].
CONCLUSION
The present study confirms the prognostic role of advance coronary atherosclerosis evaluation beyond risk factors and stenosis severity, even in diabetics. Despite the very high cardiovascular risk of study population, a not negligible portion (23%) of patients exhibited totally normal coronaries.

Identifiants

pubmed: 35109998
pii: S0939-4753(21)00554-8
doi: 10.1016/j.numecd.2021.11.013
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

586-595

Informations de copyright

Copyright © 2021 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest None declared.

Auteurs

Daniele Andreini (D)

Centro Cardiologico Monzino, IRCCS, Milan, Italy; Department of Biomedical and Clinical Sciences "Luigi Sacco", University of Milan, Milan, Italy. Electronic address: daniele.andreini@ccfm.it.

Edoardo Conte (E)

Centro Cardiologico Monzino, IRCCS, Milan, Italy.

Saima Mushtaq (S)

Centro Cardiologico Monzino, IRCCS, Milan, Italy.

Marco Magatelli (M)

Cardiology Division, Castiglione delle Siviere Hospital, Mantova, Italy.

Federica Traversari (F)

Centro Cardiologico Monzino, IRCCS, Milan, Italy.

Carlo Gigante (C)

Centro Cardiologico Monzino, IRCCS, Milan, Italy.

Marta Belmonte (M)

Centro Cardiologico Monzino, IRCCS, Milan, Italy.

Marcherita Gaudenzi-Asinelli (M)

Centro Cardiologico Monzino, IRCCS, Milan, Italy.

Andrea Annoni (A)

Centro Cardiologico Monzino, IRCCS, Milan, Italy.

Alberto Formenti (A)

Centro Cardiologico Monzino, IRCCS, Milan, Italy.

Maria E Mancini (ME)

Centro Cardiologico Monzino, IRCCS, Milan, Italy.

Marco Guglielmo (M)

Centro Cardiologico Monzino, IRCCS, Milan, Italy.

Andrea Baggiano (A)

Centro Cardiologico Monzino, IRCCS, Milan, Italy.

Eleonora Melotti (E)

Centro Cardiologico Monzino, IRCCS, Milan, Italy.

Giuseppe Muscogiuri (G)

Centro Cardiologico Monzino, IRCCS, Milan, Italy.

Maurizio Rondinelli (M)

Centro Cardiologico Monzino, IRCCS, Milan, Italy.

Gianluca Pontone (G)

Centro Cardiologico Monzino, IRCCS, Milan, Italy.

Antonio L Bartorelli (AL)

Centro Cardiologico Monzino, IRCCS, Milan, Italy; Department of Biomedical and Clinical Sciences "Luigi Sacco", University of Milan, Milan, Italy.

Mauro Pepi (M)

Centro Cardiologico Monzino, IRCCS, Milan, Italy.

Stefano Genovese (S)

Centro Cardiologico Monzino, IRCCS, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH